A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia

To determine the maximum-tolerated dose (MTD), dose-limiting toxicities and pharmacokinetic of semisynthetic homoharringtonine (ssHHT), given as a twice daily subcutaneous (s.c.) injections for 9 days, in patients with advanced acute leukaemia, 18 patients with advanced acute myeloid leukaemia were...

Descripción completa

Detalles Bibliográficos
Autores principales: Lévy, V, Zohar, S, Bardin, C, Vekhoff, A, Chaoui, D, Rio, B, Legrand, O, Sentenac, S, Rousselot, P, Raffoux, E, Chast, F, Chevret, S, Marie, J P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360653/
https://www.ncbi.nlm.nih.gov/pubmed/16847470
http://dx.doi.org/10.1038/sj.bjc.6603265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360653/
https://www.ncbi.nlm.nih.gov/pubmed/16847470
http://dx.doi.org/10.1038/sj.bjc.6603265

Ejemplares similares